.jetcityimage/iStock Content via Getty Images Morgan Stanley has opted for Eli Lilly (NYSE: LLY) as its own top biopharma selection for 2025 and ranked another nine titles in the space as overweight. The expenditure financial institution pointed out in a note that it remains to feel “diabesity is actually readied to come to be.